Gastric and Esophageal Cancer Drug Development Pipeline Review,2017 - Research and Markets

DUBLIN--()--The "Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017" report has been added to Research and Markets' offering.

This report provides an overview of the Gastric and Esophageal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for each of these cancer types, and features dormant and discontinued projects.

There are a total of 322 products in development for this indication, by 208 companies and 22 academic institutions. Key companies operating in this pipeline space include Eli Lilly, Roche, Bristol-Myers Squibb, Incyte, Pfizer and AstraZeneca.

Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. There are a total of 107 products in development for this indication, by 79 companies and 11 academic institutions.

Key targets in development across both indications include human epidermal growth factors 1 and 2, and programmed cell death protein 1. In addition, the hepatocyte and vascular endothelial growth factors are being developed across many pipeline programs in gastric cancer.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

9 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/4hqzgb/gastric_and?w=4

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Oncology Drugs